急性骨髄性白血病（AML）治療薬の世界市場2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Acute Myeloid Leukemia (AML) Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：MRC2012B0319 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Service & Software

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、急性骨髄性白血病（AML）治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。急性骨髄性白血病（AML）治療薬の種類別市場規模（化学療法、放射線療法、幹細胞移植、標的療法、その他）、用途別市場規模（病院、小売ドラッグストア、外来診療センター、腫瘍センター、クリニック）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Bristol-Myers Squibb、Genmab、Novartis、Roche、GlaxoSmithKline Pharmaceuticals、 ・地域別グローバル市場分析 2015年-2020年 ・急性骨髄性白血病（AML）治療薬の北米市場（アメリカ、カナダ、メキシコ） ・急性骨髄性白血病（AML）治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・急性骨髄性白血病（AML）治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・急性骨髄性白血病（AML）治療薬の南米市場（ブラジル、アルゼンチン） ・急性骨髄性白血病（AML）治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学療法、放射線療法、幹細胞移植、標的療法、その他 ・用途別分析：病院、小売ドラッグストア、外来診療センター、腫瘍センター、クリニック ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Acute Myeloid Leukemia (AML) Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Acute Myeloid Leukemia (AML) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Acute Myeloid Leukemia (AML) Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Acute Myeloid Leukemia (AML) Therapeutics market has been segmented into:
Chemotherapy
Radiation therapy
Stem Cell Transplant
Targeted Therapy
Others

By Application, Acute Myeloid Leukemia (AML) Therapeutics has been segmented into:
Hospital
Retails Drug Stores
Ambulatory Care Centers
Oncology Centers
Clinics

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Acute Myeloid Leukemia (AML) Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Acute Myeloid Leukemia (AML) Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Acute Myeloid Leukemia (AML) Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Acute Myeloid Leukemia (AML) Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Acute Myeloid Leukemia (AML) Therapeutics Market Share Analysis
Acute Myeloid Leukemia (AML) Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Acute Myeloid Leukemia (AML) Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Acute Myeloid Leukemia (AML) Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Acute Myeloid Leukemia (AML) Therapeutics are:
Bristol-Myers Squibb
Genmab
Novartis
Roche
GlaxoSmithKline Pharmaceuticals

レポート目次

---

Table of Contents

1 Acute Myeloid Leukemia (AML) Therapeutics Market Overview
1.1 Product Overview and Scope of Acute Myeloid Leukemia (AML) Therapeutics
1.2 Classification of Acute Myeloid Leukemia (AML) Therapeutics by Type
1.2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Radiation therapy
1.2.5 Stem Cell Transplant
1.2.6 Targeted Therapy
1.2.7 Others
1.3 Global Acute Myeloid Leukemia (AML) Therapeutics Market by Application
1.3.1 Overview: Global Acute Myeloid Leukemia (AML) Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Retails Drug Stores
1.3.4 Ambulatory Care Centers
1.3.5 Oncology Centers
1.3.6 Clinics
1.4 Global Acute Myeloid Leukemia (AML) Therapeutics Market by Regions
1.4.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Acute Myeloid Leukemia (AML) Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Acute Myeloid Leukemia (AML) Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Acute Myeloid Leukemia (AML) Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Acute Myeloid Leukemia (AML) Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Acute Myeloid Leukemia (AML) Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Acute Myeloid Leukemia (AML) Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Bristol-Myers Squibb SWOT Analysis
2.1.4 Bristol-Myers Squibb Product and Services
2.1.5 Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Genmab
2.2.1 Genmab Details
2.2.2 Genmab Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Genmab SWOT Analysis
2.2.4 Genmab Product and Services
2.2.5 Genmab Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis SWOT Analysis
2.3.4 Novartis Product and Services
2.3.5 Novartis Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 GlaxoSmithKline Pharmaceuticals
2.5.1 GlaxoSmithKline Pharmaceuticals Details
2.5.2 GlaxoSmithKline Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 GlaxoSmithKline Pharmaceuticals SWOT Analysis
2.5.4 GlaxoSmithKline Pharmaceuticals Product and Services
2.5.5 GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Acute Myeloid Leukemia (AML) Therapeutics Players Market Share
3.2.2 Top 10 Acute Myeloid Leukemia (AML) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue and Market Share by Regions
4.2 North America Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries
5.1 North America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries (2015-2020)
5.2 USA Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries
6.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries
7.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries (2015-2020)
7.2 China Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries
8.1 South America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Acute Myeloid Leukemia (AML) Therapeutics by Countries
9.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Radiation therapy Revenue Growth Rate (2015-2025)
10.5 Stem Cell Transplant Revenue Growth Rate (2015-2025)
10.6 Targeted Therapy Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Acute Myeloid Leukemia (AML) Therapeutics Market Segment by Application
11.1 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Acute Myeloid Leukemia (AML) Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Retails Drug Stores Revenue Growth (2015-2020)
11.5 Ambulatory Care Centers Revenue Growth (2015-2020)
11.6 Oncology Centers Revenue Growth (2015-2020)
11.7 Clinics Revenue Growth (2015-2020)
12 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Forecast (2021-2025)
12.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Forecast (2021-2025)
12.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Acute Myeloid Leukemia (AML) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 6. Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Major Business
Table 7. Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Bristol-Myers Squibb SWOT Analysis
Table 9. Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
Table 10. Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Genmab Corporate Information, Location and Competitors
Table 12. Genmab Acute Myeloid Leukemia (AML) Therapeutics Major Business
Table 13. Genmab Acute Myeloid Leukemia (AML) Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Genmab SWOT Analysis
Table 15. Genmab Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
Table 16. Genmab Acute Myeloid Leukemia (AML) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Novartis Corporate Information, Location and Competitors
Table 18. Novartis Acute Myeloid Leukemia (AML) Therapeutics Major Business
Table 19. Novartis Acute Myeloid Leukemia (AML) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Novartis SWOT Analysis
Table 21. Novartis Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
Table 22. Novartis Acute Myeloid Leukemia (AML) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Roche Corporate Information, Location and Competitors
Table 24. Roche Acute Myeloid Leukemia (AML) Therapeutics Major Business
Table 25. Roche Acute Myeloid Leukemia (AML) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Roche SWOT Analysis
Table 27. Roche Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
Table 28. Roche Acute Myeloid Leukemia (AML) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. GlaxoSmithKline Pharmaceuticals Corporate Information, Location and Competitors
Table 30. GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Major Business
Table 31. GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. GlaxoSmithKline Pharmaceuticals SWOT Analysis
Table 33. GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
Table 34. GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 36. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Players (2015-2020)
Table 37. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 38. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Regions (2015-2020)
Table 39. North America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries (2015-2020)
Table 40. North America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 41. Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 42. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 43. South America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Countries (2015-2020)
Table 44. South America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 45. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 46. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 47. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 48. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Type (2015-2020)
Table 49. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Forecast by Type (2021-2025)
Table 50. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue by Application (2015-2020)
Table 51. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Application (2015-2020)
Table 52. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Forecast by Application (2021-2025)
Table 53. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Acute Myeloid Leukemia (AML) Therapeutics Picture
Figure 2. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Radiation therapy Picture
Figure 5. Stem Cell Transplant Picture
Figure 6. Targeted Therapy Picture
Figure 7. Others Picture
Figure 8. Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Application in 2019
Figure 9. Hospital Picture
Figure 10. Retails Drug Stores Picture
Figure 11. Ambulatory Care Centers Picture
Figure 12. Oncology Centers Picture
Figure 13. Clinics Picture
Figure 14. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share in 2019
Figure 23. Global Top 10 Players Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 27. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Regions in 2018
Figure 28. North America Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 31. South America Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. North America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 34. North America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries in 2019
Figure 35. USA Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. Canada Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries in 2019
Figure 40. Germany Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. UK Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. France Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 43. Russia Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Italy Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries in 2019
Figure 47. China Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. Japan Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. Korea Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 50. India Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. South America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 53. South America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries in 2019
Figure 54. Brazil Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 59. UAE Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 62. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Type (2015-2020)
Figure 63. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Type in 2019
Figure 64. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share Forecast by Type (2021-2025)
Figure 65. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 66. Global Radiation therapy Revenue Growth Rate (2015-2020)
Figure 67. Global Stem Cell Transplant Revenue Growth Rate (2015-2020)
Figure 68. Global Targeted Therapy Revenue Growth Rate (2015-2020)
Figure 69. Global Others Revenue Growth Rate (2015-2020)
Figure 70. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Application (2015-2020)
Figure 71. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Application in 2019
Figure 72. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share Forecast by Application (2021-2025)
Figure 73. Global Hospital Revenue Growth Rate (2015-2020)
Figure 74. Global Retails Drug Stores Revenue Growth Rate (2015-2020)
Figure 75. Global Ambulatory Care Centers Revenue Growth Rate (2015-2020)
Figure 76. Global Oncology Centers Revenue Growth Rate (2015-2020)
Figure 77. Global Clinics Revenue Growth Rate (2015-2020)
Figure 78. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
Figure 82. Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
Figure 84. South America Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel

---